More #ASCO25 data from Roche and Jazz Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 23 May, 2025

LGBTQ+ professionals are instituting change and forging ahead in every sector of the life sciences field — and we’re spotlighting the leaders to watch at our virtual event. Join us in celebration, sign up today.

presented by Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

spotlight Endpoints News is getting a new web address: https://endpoints.news

news Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst Volastra unveils first human data of its solid tumor drug target Peer Review Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot Roche confirms overall survival benefit for PI3K inhibitor in breast cancer Jazz outlines full survival data for lung cancer drug Zepzelca GSK’s Nucala wins COPD approval, stoking rivalry with Dupixent

May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel Jun 03 11:00am ET Building robust health system partnerships for life sciences sponsored by Advisory Board Jun 18 12:00pm ET Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery sponsored by Natera Jun 26 11:00am ET May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI based CLD Platform sponsored by Rentschler Biopharma

Your ASCO25 primer: Cancer R&D meets regulatory uncertainty — how are the experts navigating the changing oncology landscape? Find out — sign up today.

endpoints pharma The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry FDA chief to senators: 3,000+ staff departures won't delay user fee targets House passes Trump tax bill with PBM and orphan drug reforms included FDA expects 'timely availability' of Covid shots as advisors update formula recommendation Cigna, Novo offer lower GLP-1 prices to lure patients to brand-name drugs

in case you missed it 1. Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact 2. Post-Hoc: AI bio needs to heed the overhyped history of CRISPR 3.